In vitro physicochemical characterization and short term in vivo tolerability study of ethionamide loaded PLGA nanoparticles: Potentially effective agent for multidrug resistant tuberculosis

Journal of Microencapsulation

Volumn 28, Issue 8, 2011, Pages 717-728

  Kumar, Gaurav ^a   Malhotra, Samir ^a   Shafiq, Nusrat ^a   Pandhi, Promila ^a   Khuller, Gopal Krishan ^a   Sharma, Sadhna ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Drug delivery; Ethionamide; Nanoparticles; Poly (lactide co glycolide); Tuberculosis

Indexed keywords

ETHIONAMIDE; POLYGLACTIN; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG RELEASE; DRUG TOLERABILITY; ENCAPSULATION; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; LIVER; LUNG; MOUSE; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; SMALL INTESTINE; SPLEEN; WEIGHT GAIN; ZETA POTENTIAL; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; FEMALE; HUMAN; INFRARED SPECTROSCOPY; MALE; ULTRASTRUCTURE;

ANIMALS; ANTITUBERCULAR AGENTS; DELAYED-ACTION PREPARATIONS; ETHIONAMIDE; FEMALE; HUMANS; LACTIC ACID; MALE; MICE; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 82255193063     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2011.615948     Document Type: Article

References (29)

1. Allemann E, Gurny R, Doelker E. Preparation of aqueous polymeric nano-dispersions by a reversible salting-out process: Influence of process parameters on particle size. Int J Pharmacol, 1992;87:247-54.
2. Auclair B, Nix DE, Adam RD, James GT, Peloquin CA. Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids. Antimicrob Agents Chemother, 2001;45:810-4. (Pubitemid 32182031)
3. Bass Jr JB, Farer LS, Hopewell PC, O'Brien R,Jacobs RF, RubenF, Snider DE, Thornton G. Treatment of tuberculosis and tuberculosis infection in adults and children. American thoracic society and the centers for disease control and prevention. Am J Crit Care Med, 1994;149:1359-74.
4. Bodmeier R, McGinity JW. The preparation and evaluation of drug containing poly (dl-lactide)microspheres formed by the solvent evaporation method. Pharm Res, 1987;4:465-71.
5. Budhian A, Siegel SJ, Winey KI. Haloperidol-loaded PLGA nanoparticles: Systematic study of particle size and drug content. Int J Pharm, 2007;336:367-75. (Pubitemid 46670649)
6. Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharm Res, 2009;26:244-9.
7. Florence AT. The oral absorption of micro-and nanoparticulates: Neither exceptional nor unusal. Pharm Res, 1997;14:259-66. (Pubitemid 27160935)
8. Florence AT, Jani PU. 1993. Particulate delivery: The challenge of the oral route. In: Rolland A, ed. Pharmaceutical particulate carriers: Therapeutic applications. New York: Marcel Dekker, p. 82.
9. Hall JB, Dobrovolskaia MA, McNeil SE. Characterization of nanoparticles for therapeutics. Nanomedicine, 2007;2:789-803.
10. Hariharan S, Bhardwaj V, Bala I, Sitterberg J, Bakowsky U, Ravi Kumar MNV. Design of estradiol loaded PLGA nanoparticulate formulations: A potential oral delivery system for hormone therapy. Pharm Res, 2006;23:184-95. (Pubitemid 43214675)
11. Italia JL, Yahya MM, Singh D, Ravi Kumar MNV. Biodegradable nanopar-ticles improve oral bioavailabilty of Amphotericin B and show reduced nephrotoxicity compared to intravenous fungizone. Pharm Res, 2009;26:1324-31.
12. James GT, MeCarthy E. Improved high performance liquid chromato-graphic assay for the determination of ethionamide in serum. J Chromatography, 1991;563:472-5.
13. Jani P, Halbert GW, Langridge J, Florence AT. Nanoparticle uptake by the rat gastrointestinal mucosa: Quantitation and particle size dependency. J Pharm Pharmacol, 1990;42:821-6.
14. Jenkins PG, Howard KA, Blackhall NW, Thomas NW, Davis SS, O'Hagan DT. Microparticle absorption from rat intestine. J Control Release, 1994;29:339-50.
15. Kumar G, Sharma S, Shafiq N, Pandhi P, Khuller GK, Malhotra S. Pharmacokinetics and tissue distribution studies of orally administered nanoparticles encapsulated ethionamide used as potential drug delivery system in management of multi-drug resistant tuberculosis. Drug Deliv, 2011;18:65-73.
16. Lamprecht A, Ubrich N, Yamamoto H, Schafer U, Takeuchi H, Lehr CM, Maincent P, Kawashima Y. Design of rolipram-loaded nanoparticles: Comparison of two preparation methods. J Control Release, 2001a;71:297-306. (Pubitemid 32276049)
17. Lamprecht A, Ubrich N, Yamamoto H, Schafer U, Takeuchi H, Maincent P, Kawashima Y, Lehr CM. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther, 2001b;299:775-81.
18. Mainardes RM, Evangelista RC. PLGA nanoparticles containing praziquan-tel: Effect of formulation variables on size distribution. Int J Pharm, 2005;290:137-44. (Pubitemid 40139053)
19. Martin A, Camacho M, Portaels F, Palomino JC. Resazurin microtiter assay plate testing of Mycobacterium tuberculosis susceptibilities to second-line drugs: Rapid, simple, and inexpensive method. Antimicrob Agents Chemother, 2003;47:3616-9. (Pubitemid 37345731)
20. Nahar M, Mishra D, Dubey V, Jain NK. Development, characterization, and toxicity evaluation of amphotericin B-loaded gelatin nanoparticles. Nanomedicine, 2008;4:252-61.
21. O'Hagan DT. Intestinal translocation of particulates-implications for drug and antigen delivery. Adv Drug Deliver Rev, 1990;5:265-85. (Pubitemid 20333028)
22. Pandey R, Khuller GK. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. J Antimicrob Chemother, 2004;54:266-8. (Pubitemid 39029006)
23. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother, 2003a;52:981-6. (Pubitemid 38008419)
24. Pandey R, Zahoor A, Sharma S, Khuller GK. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis, 2003b;83:373-8. (Pubitemid 37464042)
25. Rojas J, Pinto-Alphandary H, Leo E, Pecquet S, Couvreur P, Fattal E. Optimization of the encapsulation and release of beta-lactoglobulin entrapped poly (DL-lactide-co-glycolide) microspheres. Int J Pharm, 1999;183:67-71. (Pubitemid 29248831)
26. Sahana DK, Mittal G, Bhardwaj V, Ravi Kumar MNV. PLGA nanoparticles for oral delivery of hydrophobic drugs: Influence of organic solvent on nanoparticle formation and release behavior in vitro and in vivo using estradiol as a model drug. J Pharm Sci, 2007;9999:1-13.
27. Sharma A, Pandey R, Sharma S, Khuller GK. Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int. J Antimicrob Agents, 2004;24:599-604. (Pubitemid 39536116)
28. Zhu M, Namdar R, Stambaugh JJ, Starke JR, Bulpitt AE, Berning SE, Peloquin CA. Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis, 2002;82:91-6. (Pubitemid 35155424)
29. Zweers MLT, Grijpma DW, Engbers GHM, Feijen J. The preparation of monodisperse biodegradable polyester nanopaticles with a controlled size. J biomed Mater Res Part B: Appl Biomater, 2003;66B:559-66. (Pubitemid 37517129)